Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris

Clinical and Experimental Dermatology

Volumn 29, Issue 3, 2004, Pages 271-272

  Gach, J E ^a   Ilchyshyn, A ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; CLOBETASOL PROPIONATE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 5; PREDNISOLONE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOPATHOLOGY; KERATINOCYTE; LYMPHOCYTE ACTIVATION; OINTMENT; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; SYMPTOM; TOPICAL TREATMENT; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGUS; TACROLIMUS;

EID: 2442654139     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01499.x     Document Type: Article

References (4)

1. Nasr IS. Topical tacrolimus in dermatology. Clin Exp Dermatol 2000; 25: 250-4.
2. Hertl M, Reichers R. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. J Dermatol 1999; 26: 748-52.
3. Nishifuji K, Amagai M, Kuwana M et al. Detection of antigen-specific B-cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol 2000; 114: 88-94.
4. Hall V, Liesegang TL, Kostick DA et al. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol 2003; 139: 1083-4.